FTSE MIB
33.959,87 -311,25 (-0,91%) Dow Jones
37.872,33 -588,59 (-1,53%) Nasdaq
15.443,74 -269,01 (-1,71%) Nikkei 225
37.628,48 -831,60 (-2,16%) Petrolio
82,26 -0,55 (-0,66%) Bitcoin EUR
59.323,34 -1.167,62 (-1,93%)
Qiagen N.V. (QIA.DE)
| Chiusura precedente | 38,58 |
| Aperto | 38,71 |
| Denaro | 37,99 x 48300 |
| Lettera | 38,00 x 51100 |
| Min-Max giorno | 37,85 - 38,72 |
| Intervallo di 52 settimane | 33,75 - 44,81 |
| Volume | |
| Media Volume | 650.109 |
| Capitalizzazione | 8,456B |
| Beta (5 anni mensile) | 0,42 |
| Rapporto PE (ttm) | 26,56 |
| EPS (ttm) | 1,43 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | 1,18 (2,94%) |
| Data ex dividendo | 30 gen 2024 |
| Stima target 1A | 47,90 |
GlobeNewswireQIAGEN N.V. to release results for Q3 2023 and hold webcast
Venlo, the Netherlands, Oct. 09, 2023 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the third quarter 2023. Press release date / time: Monday, October 30, shortly after 21:05 Frankfurt time / 20:05 London time / 16:05 New York time. (For Europe: Due to the U.S. time switch, our Press release will be published one hour earlier than usual.) Conference call date / time: Tuesday, October 31, at 14:00 Frankfurt time / 13:00 Lon
GlobeNewswireQIAGEN launches QuantiFERON-EBV RUO assay, facilitating research of cell-mediated immune response to Epstein-Barr virus
QuantiFERON-EBV RUO to help researchers understand Epstein-Barr virus (EBV) infections and related malignancies, offering a dynamic view of the host immune response // Advancing research in oncology and autoimmune diseases through measurement of T-cell responses to EBV, providing valuable insights into the virus’ role in these conditions // Further expanding portfolio of QuantiFERON cell-mediated immune response tests beyond tuberculosisVenlo, the Netherlands, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Q
GlobeNewswireQIAGEN extends AI capabilities of its NGS interpretation software QCI Interpret to enable clinical exome completeness
AI-driven literature extraction for thousands of rare disease genes fortifies and extends QIAGEN’s proprietary, human-certified content, providing complete bibliographic coverage of the clinical exome // Enhanced AI-trained phenotype driven ranking of pathogenic variants improves accuracy and efficiency of prioritizing candidate variants // New features reduce time needed for prioritization, assessment and interpretation of clinically relevant variants and facilitate access to trusted evidence f
